Clinical trial
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell…
NCT00225212 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00225212 |
|---|---|
| Title | Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma |
| Official title | Clinical Trial Of C2B8 Monoclonal Antibody Following High Dose Therapy And Autografting In B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Stanford University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Transformed Lymphoma, Other Subtypes of B-cell Lymphoma, Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab 375 mg/m2 |
| Enrollment | 35 |
| Start date | Nov 1, 1997 |
| Primary completion | Mar 1, 2003 |
| Completion | Mar 1, 2003 |
| First posted | Sep 23, 2005 |
| Last update posted | Sep 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: